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Most current articleThe incidence of colorectal cancer (CRC) in the United States is increasing among adults
younger than 50 years, but incidence has decreased among older populations after population-
based screening was recommended in the late 1980s. Blacks have higher incidence than whites.
These patterns have prompted suggestions to lower the screening age for average-risk pop-
ulations or in blacks. At the same time, there has been controversy over whether reductions in
CRC incidence can be attributed to screening. We examined age-related and race-related dif-
ferences in CRC incidence during a 40-year time period.METHODS: We determined the age-standardized incidence of CRC from 1975 through 2013 by using the
population-based Surveillance, Epidemiology, and End Results (SEER) program of cancer reg-
istries. We calculated incidence for 5-year age categories (20–24 years through 80–84 years and
85 years or older) for different time periods (1975–1979, 1980–1984, 1985–1989, 1990–1994,
1995–1999, 2000–2004, 2005–2009, and 2010–2013), tumor subsite (proximal colon,
descending colon, and rectum), and stages at diagnosis (localized, regional, and distant). Ana-
lyses were stratified by race (white vs black).RESULTS: There were 450,682 incident cases of CRC reported to the SEER registries during the entire
period (1975–2013). Overall incidence was 75.5/100,000 white persons and 83.6/100,000
black persons. CRC incidence peaked during 1980 through 1989 and began to decrease in 1990.
In whites and blacks, the decreases in incidence between the time periods of 1980–1984 and
2010–2013 were limited to the screening-age population (ages 50 years or older). Between
these time periods, there was 40% decrease in incidence among whites compared with 26%
decrease in incidence among blacks. Decreases in incidence were greater for cancers of the
distal colon and rectum, and reductions in these cancers were greater among whites than
blacks. CRC incidence among persons younger than 50 years decreased slightly between 1975–
1979 and 1990. However, among persons 20–49 years old, CRC incidence increased from 8.3/
100,000 persons in 1990–1994 to 11.4/100,000 persons in 2010–2013; incidence rates in
younger adults were similar for whites and blacks.CONCLUSIONS: On the basis of an analysis of the SEER cancer registries from 1975 through 2013, CRC incidence
decreased only among individuals 50 years or older between the time periods of 1980–1984 and
2010–2013. Incidence increased modestly among individuals 20–49 years old between the time
periods of 1990–1994 and 2010–2013. The decision of whether to recommend screening for
younger populations requires a formal analysis of risks and benefits. Our observed trends pro-
vide compelling evidence that screening has had an important role in reducing CRC incidence.Keywords: Colon Cancer; Epidemiology; Endoscopy; Tumor; Early Detection.er: CRC, colorectal cancer; FOBT, fecal
veillance, Epidemiology, and End Results.
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olorectal cancer (CRC) incidence and mortality inCthe United States have changed strikingly in
recent decades.1 Overall CRC incidence declined by more
than 30% from 1975 (59.5 per 100,000) to 2013 (37.9
per 100,000),2 with particularly steep declines among
those older than the age of 65. Mortality rates have
similarly declined during the same period.1
The declines in CRC incidence have not occurred
equally in all populations. In sharp contrast to the
decline in CRC incidence and mortality among older in-
dividuals, incidence is actually rising in adults younger
than age 50.3–11 These findings have led to recommen-
dations to extend screening among average-risk in-
dividuals to ages younger than 50 years.12–14 Because
blacks have higher CRC incidence than whites and the
age-related acceleration in incidence starts at a younger
age, calls have also been made to lower the screening age
for blacks.15–18
At the same time, there has been controversy
regarding the role of screening in the reductions in CRC
incidence. Unlike screening for other cancers (eg, breast,
prostate), CRC screening reduces incidence via excision
of premalignant lesions. The use of CRC screening has
become increasingly common in the United States since it
was first formally recommended in the late 1980s
(largely driven by the use of colonoscopy),19–22 but the
extent to which it explains declines in CRC incidence has
been debated. Some have argued that screening accounts
for much of the improvement in incidence and mortality,
as observed in clinical trials of fecal occult blood testing
(FOBT) and sigmoidoscopy.23–25 However, others have
suggested that screening has had only a modest impact,
and changes in the prevalence of risk factors may be
more important.26,27
The trends in CRC incidence raise 2 related questions:
what is the role of screening in explaining the declining
rates? Which populations should be screened? To clarify
these questions and better understand the clinical and
public health implications of CRC incidence trends, we
examined age-related and race-related differences in
incidence during a 40-year time period.
Methods
Incidence of invasive CRC was derived from the Na-
tional Cancer Institute’s Surveillance, Epidemiology, and
End Results (SEER) program during 1973–2013. SEER
routinely collects data on patient demographics, primary
tumor site, tumor morphology, and stage for all cancers
diagnosed in defined geographic regions. The SEER 9
registries cover approximately 10% of the U.S. popula-
tion and include Atlanta, Connecticut, Detroit, Hawaii,
Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget
Sound, and Utah. Age-adjusted incidence (by using the2000 U.S. standard population) was obtained by using
SEER*Stat version 8.2.1 as incidence rates per 100,000
persons.
To account for differences in incidence by age, we
estimated incidence rates across 5-year age categories
(20–24 to 80–84 and 85þ) by time period, tumor sub-
site, and stage at diagnosis. We divided the study period
into 8 approximate 5-year time periods (1975–1979,
1980–1984, 1985–1989, 1990–1994, 1995–1999,
2000–2004, 2005–2009, and 2010–2013). Tumor sub-
sites included proximal colon (cecum, ascending colon,
hepatic flexure, transverse colon), descending colon
(splenic flexure, descending colon, sigmoid colon), and
rectum (rectosigmoid junction, rectum) according to the
International Classification of Disease for Oncology, 3rd
edition. Stage at diagnosis was based on SEER summary
staging. Localized disease was defined as being limited to
the large bowel, regional as limited to nearby lymph
nodes or other organs, and distant disease as systemic
metastasis.
To illustrate trends, we plotted incidence rates by age,
contrasting time periods, tumor subsites, and stages at
diagnosis. All analyses were stratified by race (white vs
black). Corresponding 95% confidence intervals were
calculated as modified gamma intervals.18
This study was approved by the Institutional Review
Board at the University of North Carolina at Chapel Hill
(#15-1957).Results
There were 450,682 incident cases of CRC diagnosed
during the entire period 1975–2013. Overall incidence
was 75.5 per 100,000 and 83.6 per 100,000 among
whites and blacks, respectively. Detailed incidence rates
by age, time period, tumor subsite, and stage at diagnosis
are available in Supplementary Table 1 (whites) and
Supplementary Table 2 (blacks).
Incidence peaked during 1980–1989, with a subse-
quent decline beginning around 1990. In both whites
(Figure 1A) and blacks (Figure 1C), the declines in inci-
dence between 1980–1984 and 2010–2013 were limited
to the screening-age population. Incidence curves
diverged sharply from previous years, but only at ages
50 years and older. However, whites experienced a
greater decline, 40% decrease (from 90.4 to 54.0 per
100,000) versus only 26% (from 90.7 to 67.2 per
100,000) among blacks. For persons aged 65–69 years,
CRC incidence in whites decreased by 51% (from 228.7
to 113.2 per 100,000) from 1980–1984 to 2010–2013
compared with 19% decrease (from 214.2 to 173.2 per
100,000) for blacks.
In younger populations (<50 years), there were hints
of decreases in incidence between 1975–1979 and about
1990, differing by 5-year age group and time period.
Subsequently, in marked contrast to populations older
than age 50, there were continued increases through to
Figure 1. Age-adjusted (2000 U.S. standard population) incidence of colorectal cancer by age group and time period
(1980–1984 vs 2010–2013a) for (A) whites, all ages; (B) whites, age <50; (C) blacks, all ages; and (D) blacks, age <50, SEER 9,
1975-2013. aWe chose to compare incidence rates from the most recent time period (2010–2013) with 1980–1984 in the figure
because incidence peaked in 1980–1984 and subsequently declined through to 2013. Shaded regions in figure denote 95%
confidence intervals.
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rates increased from 8.3 per 100,000 in 1990–1994 to
11.4 per 100,000 in 2010–2013. This difference of 3.1
per 100,000 was a 37% increase, similar in whites
(Figure 1B) and blacks (Figure 1D).
Declines in CRC incidence by tumor subsite were also
limited to screening-age populations. At ages older than
50, the incidence of distal colon and rectal cancers
decreased substantially from 1980–1984 to 2010–2013
for both whites and blacks (Figure 2). Declines in the
incidence of proximal colon cancer were smaller, and for
blacks, incidence differed little over time. Although
blacks consistently had higher overall (and age-specific)
CRC rates than whites, they had lower rectal cancer rates
overall (19.8 per 100,000 in blacks vs 21.5 per 100,000
in whites) and in older age groups (Supplementary
Tables 3 and 4).
Among whites, incidence of local, regional, and distant
disease each decreased from 1980–1984 to 2010–2013
(Supplementary Figure 1), only at ages 50 and older.
There was very little decrease in incidence of local disease
among blacks (and limited to the oldest ages). For the
screening-age population, the absolute difference inincidence of distant disease between whites and blacks
was generally about 15 per 100,000. The higher incidence
of metastatic disease among blacks accounted for essen-
tially all of the differences in overall CRC rates between
whites and blacks (Supplementary Tables 5 and 6).
Discussion
Trends in incidence across age, race, subsite, and
stage provide compelling evidence of the impact of
screening on CRC incidence in the United States. Specif-
ically, the dramatic decline in CRC incidence from its
peak in the 1980s to 2010–2013 occurred exclusively
among individuals older than age 50, the recommended
age for the initiation of CRC screening in average-risk
populations. Moreover, incidence rates have fallen most
prominently in the distal colorectum, where screening
most reduces cancer incidence.28–31
The differences in CRC incidence by race offer addi-
tional support for the impact of screening. As noted by
others,32–37 blacks have experienced smaller declines in
incidence over time (particularly for localized disease), as
would be expected in a population that historically has
Figure 2. Age-adjusted (2000 US standard population) incidence of (A) proximal colon cancer in whites; (B) descending colon
cancer in whites; (C) rectal cancer in whites; (D) proximal colon cancer in blacks; (E) descending colon cancer in blacks; (F)
rectal cancer in blacks, by age group and time period (1980-1984 vs. 2010-2013), SEER 9, 1975-2013. Proximal colon includes
the cecum, ascending colon, hepatic flexure, and transverse colon; descending colon includes the splenic flexure, descending
colon, and sigmoid colon; rectum includes the rectosigmoid junction and rectum. Shaded regions in figure denote 95%
confidence intervals.
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that blacks presented more frequently with metastatic
disease, a difference that accounted for much of the dif-
ferences in the overall rates with whites, may also be
related to lower use of screening. In addition, there is
evidence that blacks have been screened less effectively
than whites, more frequently with FOBT and less
frequently with colonoscopy.19 The effectiveness of FOBT
may be reduced when patients do not adhere to a regular
schedule.40–43 Evidence is limited concerning differences
in adherence by race, but the prevalence of repeat FOBT
remains low, between 14% and 54%.44–47 FOBT or
sigmoidoscopy screening alone may also miss proximal
cancers, which are more common in blacks.15,48–52 Our
findings support efforts to target screening programs in
the underserved and the need for tailored interventions
that address minority populations.53
There were no continued declines in CRC incidence
among younger adults, a population that is not regularly
screened. The relative increases in incidence summa-
rized above, combined with the benefits of screening
observed in older populations, have led some to promote
changing screening guidelines to begin average-risk
screening at a younger age, such as age 40,13,14 or in
blacks.15–18 Indeed, the relative increases in incidence
rates in younger populations are dramatic, and the
temptation is to believe the clinical implications are
equally important. However, these relative increases are
based on an absolute increase of only a few additional
cases per 100,000 persons during a 20-year time period.For example, at age 45–49, the relative increase in inci-
dence from 1990 to 2013 is nearly 30%, but the absolute
difference during the same time period is a modest 6.4
cases per 100,000. The differences are even smaller for
younger ages. Consequently, it is not clear whether it is
appropriate to lower the recommended age at screening.
To ensure a net benefit, such a recommendation should
assess all benefits and harms in absolute terms, not
solely on relative changes in one outcome, CRC inci-
dence.54 These considerations also pertain to the ques-
tion of whether blacks should be recommended to start
CRC screening at an earlier age.
There are factors other than screening that could
account for some of the reductions in CRC incidence. The
large declines in certain CRC risk factors (eg, smoking,55
red and processed meat consumption56) have likely
contributed to lower incidence rates. Yet obesity, a clear
risk factor for CRC,57 has been increasing in preva-
lence,58 whereas CRC incidence continues to decline in
adults of screening age. These temporal trends in risk
factors are not biologically consistent with the divergent
incidence trends in younger and older populations. It is
unlikely that risk factor trends would parallel the de-
clines in incidence among older populations but be
inversely related to incidence rates in younger adults
(age <50). Changes in the prevalence of risk factors
across the U.S. population may play only a minor role in
CRC incidence patterns.
Concerns have also been raised regarding the timing
of the decline in CRC incidence relative to
June 2017 Screening and Colorectal Cancer Incidence 907recommendations for population-based screening.27 In
the early 1980s, scientific evidence began supporting the
effectiveness of population-based screening with FOBT
or sigmoidoscopy, which was based on findings from
feasibility studies in the United States59 and European
trials.60 Screening targets were subsequently included in
the National Cancer Institute’s 1987 working guidelines
on the early detection of cancer.61 Uptake of CRC
screening has been slow compared with other cancer
screenings (eg, breast, cervical). However, national sur-
veys62 as early as 1982 showed nearly half (44%) of men
and women had ever received FOBT. Our finding that the
incidence of distal colon and rectal cancer started to
decline around 1985–1989 is consistent with this early
adoption of stool-based screening tests. The decline in
the incidence of proximal cancer did not start until
the early 2000s (and in 2005–2009 for blacks;
Supplementary Tables 3 and 4), which may correspond
to more recent trends favoring colonoscopy as the
preferred screening modality.29
Others27 describing declines in CRC mortality (vs
incidence) during a similar time period have commented
that screening does not fully explain recent trends. We
have discussed the effects of CRC “screening,” but it is
important to keep in mind the distinction between early
cancer detection and the removal of premalignant lesions
through polypectomy. An integral component of the CRC
screening program in the United States, polypectomy
affects incidence to a greater extent than it does mor-
tality. On the other hand, CRC mortality has a broader set
of influences than incidence, such as treatment advances
or earlier evaluation of symptomatic cancers. We focused
exclusively on patterns of CRC incidence to provide a
clear picture of the impact of screening.
There are some limitations of cancer incidence data,
which may not be uniformly accurate for all populations
(including racial/ethnic minorities) and geographic re-
gions. We did not have the ability to examine incidence
rates in populations other than white and black race.
Although CRC incidence is generally lower in Asian and
Hispanic populations, some evidence shows rates are
increasing among them.63,64 We also had incomplete data
on stage and anatomic subsite. In addition, cancer reg-
istries do not provide information about the prevalence
of risk factors or screening in the population, limiting the
ability to study incidence patterns in conjunction with
secular trends.
In summary, patterns of CRC incidence point to
screening as an important underlying explanation for the
large declines in incidence. It is unlikely that
the declining incidence rates are due to changes in the
prevalence of risk factors over time. Reductions in inci-
dence begin around age 50, are more prominent in the
distal colorectum, and are less marked in blacks. These
trends suggest screening has played a dominant role in
declines in CRC incidence. As incidence in older adults
has declined, the proportion of cancers diagnosed under
age 50 has increased, apparently alarmingly. Theabsolute increase in incidence before age 50 is modest,
and the question of screening in younger populations
requires a formal analysis of risks and benefits. However,
it is clear that achieving the public health goal of 80%
screening adherence in age-eligible populations65,66
could avert more than 200,000 new cancer cases and
deaths in the next 20 years.67 Continued work to
improve the uptake of CRC screening in older and mi-
nority populations may result in further improvements
in CRC outcomes.Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at http://dx.doi.org/10.1016/j.cgh.2016.08.037.References
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Supplementary Figure 1. Age-adjusted (2000 U.S. standard population) incidence of local, regional, and distant stage
colorectal cancer by age group and time period (1980–1984 vs 2010–2013) for whites and blacks, SEER 9, 1975-2013. SEER
summary staging describes localized disease as limited to large bowel, regional as limited to nearby lymph nodes or other
organs, and distant disease as systemic metastases. Shaded regions in figure denote 95% confidence intervals.
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Supplementary Table 1. Age-adjusted Incidence (per 100,000 Persons) of CRC by Age, Time Period, Tumor Subsite, and
SEER Summary Stage for Whites, SEER 9, 1975–2013
Age (y)
Overall
(all ages)20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85þ
Overall 0.8 1.6 3.5 6.8 13.6 26.4 50.8 79.7 125.0 189.7 263.4 337.8 405.2 433.6
Time period
1975–1779 0.6 1.6 3.5 6.8 14.2 29.7 53.9 92.8 148.3 222.6 307.8 390.8 468.9 519.6 87.3
1980–1984 0.7 1.0 2.7 6.0 12.7 28.0 55.0 95.6 152.1 228.7 316.1 414.3 501.2 556.4 90.4
1985–1989 0.4 1.1 2.8 5.3 11.5 25.2 52.0 94.5 154.8 222.0 315.0 416.1 500.6 547.3 89.2
1990–1994 0.4 1.3 3.0 5.7 12.0 22.9 46.3 86.5 140.2 209.6 282.3 370.4 461.4 482.5 81.1
1995–1999 0.6 1.7 3.3 6.3 12.3 24.1 44.9 82.7 132.3 200.8 274.8 343.0 427.7 466.7 77.6
2000–2004 1.1 1.8 3.8 7.3 13.6 25.6 50.2 75.5 120.0 183.9 247.1 319.7 378.1 424.4 72.3
2005–2009 1.1 2.4 4.7 8.4 15.7 27.6 51.8 67.2 96.2 150.2 209.8 263.8 325.6 353.3 63.1
2010–2013 1.4 2.6 5.1 9.1 17.4 29.3 53.1 58.6 78.4 112.0 158.3 211.2 267.5 287.6 53.2
Tumor subsite
Proximal 0.2 0.4 0.9 1.8 3.6 6.7 12.9 22.5 38.6 65.6 103.0 145.6 190.3 209.4 28.8
Descending 0.2 0.4 1.0 1.9 4.1 8.3 16.5 25.7 40.4 60.2 79.1 96.6 104.1 97.8 21.9
Rectum 0.2 0.5 1.2 2.4 5.0 10.0 19.4 28.3 41.3 57.1 71.6 82.1 89.9 88.1 21.1
Unspecified 0 0.1 0.2 0.2 0.4 0.7 1.1 2.0 3.4 5.4 8.0 12.0 19.2 36.8 2.9
Summary stage
Localized 0.3 0.6 1.2 2.2 4.6 9.5 20.4 31.1 48.8 77.3 106.8 135.9 157.2 149.1 29.3
Regional 0.3 0.6 1.3 2.7 5.3 10.0 18.3 29.2 46.1 68.5 96.1 121.3 144.9 140.0 27.1
Distant 0.2 0.4 0.8 1.7 3.2 6.0 10.3 16.5 25.2 36.4 48.5 58.9 69.9 71.3 14.2
Unstaged 0 0.1 0.2 0.2 0.5 0.8 1.8 2.9 4.8 7.5 12.1 18.3 33.2 73.3 4.8
NOTE. For all rates displayed in the table, the coefficient of variation was less than 5%, with exception of youngest ages (eg, 20–24 years), where rates are near 0.
Supplementary Table 2. Age-adjusted Incidence (per 100,000 Persons) of CRC by Age, Time Period, Tumor Subsite, and
SEER Summary Stage for Blacks, SEER 9, 1975–2013
Age (y)
Overall
(all ages)20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85þ
Overall 0.6 1.9 4.1 9.1 18.3 35.7 71.6 105.3 154.2 211.3 278.8 347.4 405.3 393.3
Time period
1975–1979 0.8 2.0 3.7 9.3 15.8 34.3 63.4 104.1 137.2 180.8 275.6 358.3 434.3 449.8 82.3
1980–1984 0.3 1.8 4.7 8.2 20.1 30.9 60.9 108.4 173.0 214.2 314.1 384.4 522.2 446.2 90.8
1985–1989 0.4 1.8 3.3 10.4 18.1 34.8 69.8 110.1 175.7 253.9 301.2 379.3 448.4 399.8 90.4
1990–1994 0.5 1.7 4.0 9.9 18.1 36.6 72.0 113.0 169.1 235.0 322.9 377.5 459.2 437.7 91.7
1995–1999 0.9 2.2 4.1 7.8 16.1 35.1 68.9 108.4 166.7 223.3 299.3 369.6 431.3 420.8 87.5
2000–2004 0.5 1.7 4.2 9.6 18.8 35.7 70.8 113.6 171.2 225.5 276.8 377.2 428.7 454.3 88.8
2005–2009 0.8 1.8 4.2 8.9 20.2 35.8 82.5 102.7 142.4 193.1 260.2 299.0 353.7 384.6 79.0
2010–2013 0.6 2.5 4.8 8.7 18.0 39.1 71.5 92.5 122.8 173.2 199.9 261.6 277.9 260.8 66.8
Tumor subsite
Proximal 0.1 0.5 1.3 2.9 6.1 11.9 24.6 39.4 59.7 85.1 119.5 158.7 191.3 185.5 34.7
Descending 0.2 0.5 1.0 2.4 5.5 10.1 20.8 31.5 48.3 66.6 86.0 99.5 109.9 97.2 24.4
Rectum 0.2 0.7 1.4 3.1 5.5 11.7 23.2 30.0 39.1 49.7 60.3 71.3 76.8 65.8 19.7
Unspecified 0 0.1 0.3 0.5 0.7 1.4 2.2 3.4 5.8 8.2 11.0 15.3 25.0 43.0 4.1
Summary stage
Localized 0.1 0.5 1.5 3.0 5.7 11.1 28.2 39.4 55.8 77.5 100.8 128.0 140.5 121.4 29.7
Regional 0.2 0.9 1.4 3.0 7.0 13.1 23.6 34.6 53.1 70.0 95.5 112.5 127.0 103.7 27.3
Distant 0.2 0.4 1.1 2.5 4.8 9.8 16.9 26.1 37.7 52.4 64.7 79.9 88.9 86.3 19.8
Unstaged 0 0.2 0.2 0.6 0.8 1.7 2.9 5.2 7.6 11.4 17.8 27.0 48.8 81.8 6.8
NOTE. For all rates displayed in the table, the coefficient of variation was less than 10%, with exception of youngest ages (eg, 20–24 years), where rates are near 0.
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Supplementary Table 3. Age-adjusted Incidence (per 100,000 Persons) of CRC by Age, Tumor Subsite, and Time Period for
Whites, SEER 9, 1975–2013
Age (y)
20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85þ
Proximal colon
1975–1979 0.1 0.5 1.0 2.0 4.2 8.0 14.2 24.6 41.1 68.7 107.3 148.4 191.2 203.8
1980–1984 0.1 0.3 0.8 2.0 3.7 7.7 13.8 25.3 41.6 71.5 108.5 159.8 211.7 242.7
1985–1989 0.1 0.3 1.1 1.6 3.3 6.3 14.2 24.6 43.8 70.0 113.9 163.7 213.2 243.7
1990–1994 0.1 0.3 0.8 1.8 3.7 6.7 14.2 25.9 42.8 70.3 106.0 154.2 208.0 230.5
1995–1999 0.2 0.5 0.9 1.6 2.9 5.8 13.7 24.1 43.4 72.0 113.0 151.6 202.9 233.0
2000–2004 0.3 0.5 0.9 1.9 3.6 6.3 14.4 22.2 40.9 69.3 105.2 147.1 191.5 217.0
2005–2009 0.3 0.4 1.1 1.8 3.8 6.5 14.9 20.5 33.9 60.0 96.0 130.9 170.4 187.3
2010–2013 0.2 0.4 0.9 1.9 3.7 6.8 13.6 16.5 26.7 45.4 71.6 109.0 148.1 153.1
Distal colon
1975–1979 0.2 0.3 1.0 2.2 4.9 11.3 19.3 32.8 51.9 74.4 100.0 119.6 130.7 134.2
1980–1984 0.2 0.2 0.8 1.9 4.6 9.6 20.5 34.9 56.2 78.6 104.7 135.8 146.1 145.3
1985–1989 0.1 0.2 0.7 1.6 3.6 8.3 19.3 34.6 54.6 79.1 102.5 132.3 149.3 143.0
1990–1994 0.1 0.4 0.8 1.6 3.4 7.6 15.4 28.9 47.4 70.4 88.9 109.8 129.6 115.8
1995–1999 0.1 0.5 0.8 1.9 3.5 7.5 13.6 25.6 41.3 60.3 79.0 95.5 107.6 103.1
2000–2004 0.3 0.4 0.9 1.9 3.9 7.4 15.4 22.5 36.0 54.4 70.0 86.6 87.5 87.6
2005–2009 0.3 0.6 1.2 2.3 4.3 7.9 15.8 19.2 26.3 40.9 52.7 62.0 70.8 68.2
2010–2013 0.3 0.7 1.6 2.3 5.0 8.1 15.0 15.5 19.7 28.4 38.3 45.5 52.1 51.2
Rectum
1975–1979 0.1 0.4 1.0 1.8 4.1 9.2 19.4 33.0 51.0 71.9 89.8 108.1 125.2 137.6
1980–1984 0.2 0.3 0.7 1.5 4.0 9.5 19.5 32.8 50.6 71.3 92.8 103.9 119.0 125.1
1985–1989 0.1 0.3 0.8 1.7 3.9 9.6 18.0 32.1 51.7 66.8 89.4 105.5 115.4 115.7
1990–1994 0.1 0.4 1.0 1.8 4.3 7.5 16.9 28.7 44.7 62.1 78.3 91.4 101.0 92.7
1995–1999 0.3 0.6 1.2 2.3 4.9 9.6 16.8 29.8 43.0 61.4 72.7 82.2 94.3 90.3
2000–2004 0.3 0.6 1.5 2.9 5.1 10.3 19.7 27.2 38.4 52.8 61.6 73.0 79.4 81.0
2005–2009 0.4 1.0 1.9 3.5 6.2 11.4 20.4 24.4 31.1 42.6 52.2 59.2 66.3 65.5
2010–2013 0.4 0.9 1.8 4.0 7.3 12.1 22.7 22.7 27.1 32.3 39.0 45.1 50.3 53.6
NOTE. Proximal colon includes the cecum, ascending colon, hepatic flexure, and transverse colon; descending colon includes the splenic flexure, descending
colon, and sigmoid colon; rectum includes the rectosigmoid junction and rectum.
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Supplementary Table 4. Age-adjusted Incidence (per 100,000 Persons) of CRC by Age, Tumor Subsite, and Time Period for
Blacks, SEER 9, 1975–2013
Age (y)
20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85þ
Proximal colon
1975–1979 0.1 0.6 1.8 2.9 4.6 11.5 21.0 31.9 50.2 63.2 96.9 139.7 152.5 204.0
1980–1984 0.2 0.7 1.2 2.4 6.2 10.2 20.1 38.1 54.6 81.7 120.7 176.9 213.1 190.0
1985–1989 0.1 0.3 1.1 4.7 6.9 10.4 22.6 42.0 62.3 92.5 120.1 152.4 183.3 151.5
1990–1994 0.2 0.3 1.2 3.6 7.0 12.2 27.2 45.1 65.7 87.7 138.0 169.9 208.0 185.8
1995–1999 0.3 0.9 1.4 2.5 5.8 11.6 23.6 40.4 63.5 92.7 134.3 166.1 205.3 199.6
2000–2004 0.2 0.6 1.5 3.1 5.8 12.2 26.2 43.0 73.7 95.4 125.5 178.2 215.7 230.9
2005–2009 0.2 0.2 1.3 2.1 6.0 12.1 28.4 39.2 59.4 89.9 119.6 145.9 189.7 201.0
2010–2013 0.0 0.6 1.3 1.7 6.0 13.2 22.5 36.0 50.1 73.8 94.7 136.2 150.6 130.4
Distal colon
1975–1979 0.5 0.6 0.3 3.6 6.2 12.6 22.3 34.7 46.1 67.1 91.1 133.3 147.2 122.9
1980–1984 0.1 0.4 1.9 3.4 5.9 11.0 22.5 36.7 67.8 70.6 115.5 115.8 179.2 132.6
1985–1989 0.0 0.5 1.2 2.5 5.5 11.8 24.8 36.3 62.6 97.3 108.3 128.4 148.0 124.9
1990–1994 0.1 0.2 0.9 2.3 6.0 9.9 20.6 34.5 59.3 83.4 106.8 115.3 145.9 133.4
1995–1999 0.3 0.5 1.0 1.8 4.7 9.9 21.9 32.0 52.2 68.7 87.2 104.1 113.8 97.5
2000–2004 0.1 0.3 0.9 1.9 6.1 9.2 19.6 34.5 45.5 67.4 80.2 102.3 104.9 111.7
2005–2009 0.2 0.8 1.2 2.3 5.5 7.7 21.2 28.5 40.4 48.5 68.7 70.8 78.7 78.5
2010–2013 0.2 0.8 0.7 2.7 4.8 12.0 17.7 23.8 31.2 42.6 48.4 57.1 47.1 45.6
Rectum
1975–1979 0.1 0.3 1.5 1.8 4.8 8.7 17.9 32.9 35.9 44.2 72.4 62.6 102.3 76.2
1980–1984 0.0 0.6 1.0 1.6 6.6 8.5 16.5 30.1 43.8 54.2 64.9 77.2 110.1 89.6
1985–1989 0.3 0.7 0.7 2.9 4.1 10.9 19.3 29.4 45.0 53.8 64.0 84.0 82.8 84.2
1990–1994 0.2 0.8 1.7 3.1 4.2 12.5 21.1 29.3 37.4 52.1 66.9 76.0 75.6 62.7
1995–1999 0.2 0.8 1.1 2.7 4.7 11.6 20.4 32.4 42.2 51.9 63.2 76.8 78.4 75.9
2000–2004 0.2 0.8 1.4 4.1 5.6 11.4 22.1 29.7 43.1 52.1 58.1 77.3 78.5 61.3
2005–2009 0.3 0.8 1.3 3.7 7.6 14.4 29.5 31.1 35.6 46.1 58.9 65.8 62.6 59.5
2010–2013 0.2 0.6 2.2 3.5 5.6 11.9 27.3 26.7 34.4 44.4 41.9 51.2 60.5 48.4
NOTE. Proximal colon includes the cecum, ascending colon, hepatic flexure, and transverse colon; descending colon includes the splenic flexure, descending
colon, and sigmoid colon; rectum includes the rectosigmoid junction and rectum.
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Supplementary Table 5. Age-adjusted Incidence (per 100,000 Persons) of CRC by Age, SEER Summary Stage, and Time
Period for Whites, SEER 9, 1975–2013
Age (y)
20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85þ
Localized
1975–1979 0.3 0.6 1.0 2.3 4.9 10.0 18.1 32.4 51.2 78.8 109.8 135.0 153.4 142.2
1980–1984 0.2 0.3 0.7 1.6 3.6 9.3 19.6 34.3 54.8 84.5 117.9 148.6 167.8 165.8
1985–1989 0.2 0.4 0.8 1.6 3.9 8.5 18.4 36.3 61.9 93.9 125.8 168.6 190.1 177.4
1990–1994 0.1 0.3 1.1 1.7 3.8 8.6 16.9 31.8 53.8 85.9 113.6 147.4 174.4 159.9
1995–1999 0.3 0.5 1.0 2.3 4.4 8.7 17.6 32.1 52.1 82.5 114.2 137.6 171.9 165.2
2000–2004 0.5 0.6 1.3 2.6 4.9 10.2 21.5 32.5 51.7 80.1 107.2 139.9 158.5 158.4
2005–2009 0.4 1.0 1.8 2.8 5.5 10.2 24.0 28.7 40.5 66.9 95.0 118.6 139.9 135.2
2010–2013 0.8 1.2 1.8 2.6 5.9 10.3 23.9 24.2 31.6 48.4 68.1 91.0 112.2 109.6
Regional
1975–1979 0.2 0.5 1.4 2.7 5.4 11.5 20.6 35.3 56.9 81.6 110.0 139.5 161.4 155.1
1980–1984 0.2 0.3 1.1 2.4 5.7 11.8 21.9 37.3 59.8 86.8 123.5 160.3 187.7 184.1
1985–1989 0.1 0.4 1.1 2.1 4.5 10.2 21.3 35.2 57.0 79.4 117.3 152.1 181.3 180.8
1990–1994 0.2 0.5 1.1 2.1 4.9 8.7 17.6 33.0 52.4 77.9 103.5 136.0 168.1 159.5
1995–1999 0.2 0.7 1.3 2.3 4.5 9.6 17.1 31.3 49.3 72.8 102.1 128.6 153.6 158.6
2000–2004 0.4 0.7 1.4 3.1 5.6 8.9 17.8 26.8 43.3 66.4 90.5 114.6 135.2 138.3
2005–2009 0.5 0.8 1.6 3.4 5.9 10.3 16.3 22.6 33.3 51.4 69.7 90.6 114.1 110.3
2010–2013 0.4 0.7 1.9 3.7 6.5 10.4 16.8 19.8 26.7 36.9 53.4 72.1 91.4 87.0
Distant
1975–1979 0.1 0.3 0.7 1.6 3.1 6.8 12.6 20.6 31.6 49.4 65.0 80.8 92.4 89.2
1980–1984 0.2 0.3 0.6 1.5 3.1 5.4 11.5 19.7 30.3 46.6 57.9 77.2 90.9 98.7
1985–1989 0.1 0.2 0.7 1.3 2.6 5.5 10.2 18.5 29.3 39.0 56.5 70.3 85.3 87.3
1990–1994 0.1 0.3 0.6 1.6 2.6 5.0 9.9 18.3 28.4 38.0 52.7 65.2 80.3 78.8
1995–1999 0.1 0.3 0.8 1.5 2.9 5.2 8.7 16.5 26.5 37.7 47.1 58.3 68.5 68.8
2000–2004 0.2 0.4 0.9 1.5 2.9 5.9 9.7 14.2 22.0 32.4 41.8 52.2 62.6 65.2
2005–2009 0.2 0.5 1.2 2.0 3.9 6.5 9.9 14.3 19.6 28.2 38.7 45.1 52.9 59.3
2010–2013 0.2 0.6 1.3 2.6 4.5 7.8 10.8 12.9 18.1 23.1 31.1 40.6 48.4 53.4
NOTE. SEER summary staging describes localized disease as limited to large bowel, regional as limited to nearby lymph nodes or other organs, and distant
disease as systemic metastases.
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Supplementary Table 6. Age-adjusted Incidence (per 100,000 Persons) of CRC by Age, SEER Summary Stage, and Time
Period for Blacks, SEER 9, 1975–2013
Age (y)
20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85þ
Localized
1975–1979 0.2 0.4 1.0 2.7 6.0 9.3 19.6 31.7 45.8 53.9 85.8 110.7 113.1 145.0
1980–1984 0.1 0.4 1.2 2.3 5.3 10.6 22.8 34.1 53.1 72.0 99.1 108.5 143.9 102.1
1985–1989 0.1 0.4 1.2 3.2 6.2 9.7 22.4 40.8 63.1 83.0 98.7 131.4 155.7 140.3
1990–1994 0.0 0.1 1.3 3.3 5.6 9.5 27.0 42.5 55.2 79.9 114.3 136.3 150.4 129.9
1995–1999 0.1 0.6 1.3 2.7 5.0 10.6 25.6 37.4 54.0 88.7 112.9 134.6 161.5 134.0
2000–2004 0.2 0.6 1.9 3.7 5.6 10.6 27.0 40.7 66.6 84.9 98.3 149.3 158.3 141.1
2005–2009 0.4 0.5 1.4 2.9 6.2 12.5 35.6 45.7 58.6 85.0 106.0 122.7 135.4 119.1
2010–2013 0.1 1.0 2.3 3.0 5.8 13.6 32.5 37.0 49.2 66.8 85.8 115.2 99.9 83.4
Regional
1975–1979 0.4 1.4 1.6 3.3 6.2 13.7 22.5 37.8 49.2 59.7 92.8 126.1 127.4 110.6
1980–1984 0.0 0.6 1.8 3.6 10.8 9.9 20.8 40.7 66.7 77.0 106.3 131.1 163.7 127.2
1985–1989 0.1 1.0 1.1 4.1 6.8 13.8 27.2 39.6 61.0 92.5 106.7 127.8 142.5 94.0
1990–1994 0.3 1.0 1.5 3.0 7.6 14.6 27.4 36.9 62.6 80.8 115.8 123.2 147.7 109.4
1995–1999 0.5 0.5 1.5 2.6 6.1 14.9 24.4 36.0 64.5 75.3 100.4 126.7 134.6 120.0
2000–2004 0.3 0.7 1.2 3.1 6.3 12.9 25.0 37.8 57.2 74.3 105.7 123.4 135.9 129.3
2005–2009 0.2 0.7 1.5 2.8 7.2 12.2 24.6 29.8 44.0 56.2 87.0 86.5 106.2 103.0
2010–2013 0.2 1.1 1.6 2.5 6.4 12.4 18.6 28.2 36.2 51.7 55.8 73.2 90.8 60.6
Distant
1975–1979 0.2 0.2 1.1 2.7 2.9 8.7 17.0 26.9 30.7 52.4 71.8 83.4 129.2 93.4
1980–1984 0.1 0.5 1.4 1.8 3.4 8.5 15.6 26.6 40.1 53.6 80.3 99.8 128.4 96.8
1985–1989 0.2 0.2 1.0 2.5 3.7 9.0 16.2 24.1 41.3 62.0 73.2 91.2 89.5 89.8
1990–1994 0.2 0.4 1.0 2.7 4.1 9.7 13.9 28.4 41.0 60.7 71.0 85.5 98.1 80.9
1995–1999 0.3 0.5 1.1 1.8 4.1 8.4 16.5 28.1 39.2 47.9 67.9 83.3 82.3 85.3
2000–2004 0.0 0.2 1.0 2.3 6.4 9.9 15.8 30.1 42.3 55.5 58.1 81.1 88.4 94.9
2005–2009 0.3 0.7 1.2 2.9 6.1 10.0 19.8 23.9 35.1 44.0 55.7 68.3 79.9 90.4
2010–2013 0.2 0.5 0.7 2.9 4.9 12.1 17.7 23.5 34.1 46.9 49.7 58.6 63.3 71.2
NOTE. SEER summary staging describes localized disease as limited to large bowel, regional as limited to nearby lymph nodes or other organs, and distant
disease as systemic metastases.
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